Clinical Trials Arena on MSN
Kolon TissueGene’s stock drops on Phase III knee osteoarthritis trial failure
Kolon TissueGene’s stock dropped nearly 30% after the Phase III knee osteoarthritis trial failure.
Three years after gaining three liver disease assets in its $952 million buyout of Albireo, Ipsen is struggling to develop ...
Key Points Interested in Astrazeneca Plc? Here are five stocks we like better. Wainua failed its CARDIO-TTRansform Phase 3 trial by showing no additive benefit for patients already taking stabilizer ...
A phase 2 study of Celldex’s barzolvolimab in a chronic skin disease has missed its primary endpoint, driving the biotech to ...
Two Sarepta Therapeutics drugs for treating different genetic subsets of patients with Duchenne muscular dystrophy failed the confirmatory study required of their accelerated FDA approvals. Sarepta ...
BioCardia’s data safety monitoring board already warned that the phase 3 CardiAMP cell therapy heart failure trial was not going to make the primary endpoint. And so the California biotech is ...
Bayer’s Kerendia, already FDA approved in one cardiometabolic indication, now has data from a pivotal test that support expanding the drug’s label to heart failure. In preliminary results reported ...
CardiAMP cell therapy-treated patients had 37% relative risk reduction in heart death equivalent (death, heart transplant, left ventricular assist device implantation) and 9% relative risk reduction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results